Guggenheim began coverage on shares of Mylan (NASDAQ:MYL) in a research note released on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $59.00 price objective on the stock.

Several other brokerages also recently weighed in on MYL. UBS set a $46.00 price target on Mylan and gave the company a buy rating in a research note on Monday, December 4th. ValuEngine upgraded Mylan from a hold rating to a buy rating in a research note on Friday, December 1st. Cantor Fitzgerald set a $34.00 price target on Mylan and gave the company a hold rating in a research note on Thursday, November 30th. Zacks Investment Research downgraded Mylan from a buy rating to a hold rating in a research note on Wednesday, November 8th. Finally, Royal Bank of Canada boosted their price target on Mylan from $32.00 to $37.00 and gave the company a sector perform rating in a research note on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the stock. Mylan has an average rating of Buy and a consensus target price of $42.41.

Shares of Mylan (NASDAQ MYL) traded up $0.48 during trading hours on Tuesday, hitting $40.49. The stock had a trading volume of 7,298,706 shares, compared to its average volume of 6,044,617. Mylan has a twelve month low of $29.39 and a twelve month high of $45.87. The stock has a market cap of $21,205.33, a P/E ratio of 8.41, a PEG ratio of 2.17 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95.

Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). Mylan had a net margin of 7.28% and a return on equity of 20.63%. The company had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. During the same quarter in the prior year, the business posted $1.38 earnings per share. The company’s revenue was down 2.3% compared to the same quarter last year. sell-side analysts forecast that Mylan will post 4.56 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MYL. Meeder Asset Management Inc. raised its holdings in Mylan by 76.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after purchasing an additional 1,475 shares during the period. BT Investment Management Ltd purchased a new stake in Mylan during the 3rd quarter worth approximately $142,000. Global X Management Co. LLC increased its stake in Mylan by 59.2% during the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock worth $186,000 after buying an additional 1,786 shares in the last quarter. Doliver Capital Advisors LP purchased a new stake in Mylan during the 2nd quarter worth approximately $201,000. Finally, Sheaff Brock Investment Advisors LLC purchased a new stake in Mylan during the 2nd quarter worth approximately $210,000. 75.04% of the stock is owned by institutional investors.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/15/mylan-myl-research-coverage-started-at-guggenheim.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Stock Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related stocks with our FREE daily email newsletter.